BAM
RXST icon

Belpointe Asset Management’s RxSight RXST Stock Holding History

Belpointe Asset Management’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-105,250
Closed -$1.76M – 2814
2023
Q1 		$1.76M Buy
+105,250
New +$1.49M 0.09% 221

Other funds holding RXST

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Belpointe Asset Management's RXST Position: Q2 2023 in Review

Belpointe Asset Management sold out of RxSight (RXST) in Q2 2023, closing a stake of 105,250 shares — an estimated $1.76M sold.

Belpointe Asset Management first reported a position in RXST in Q1 2023 and held it in 1 quarter. The position peaked at $1.76M in Q1 2023. 115 funds tracked by Wall St. Rank hold RXST as of Q2 2023.

  • Belpointe Asset Management reported no remaining RxSight position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 105,250 RxSight shares in Q2 2023, an estimated $1.76M.
  • Belpointe Asset Management first reported a position in RxSight in Q1 2023 and held it in 1 quarter.
  • Belpointe Asset Management's RxSight position peaked at $1.76M in Q1 2023.
  • 115 funds tracked by Wall St. Rank held RxSight as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.